Well, Drs. Kaminsky and Missling would not be appearing together to announce that the preparations for the clinical trial and the trial itself is a dud. Moreover, this is telling in a very positive way:
“World Orphan Drug Congress USA 2018 - Conference Day One @ 11:25
Empowered educated patients influencing pre-clinical development and working with industry to optimize drug discovery
Patient groups role guiding research, disease understanding, supporting pre-clinical development and follow up experiments
Driving translational research and the influence on formulation, routes to delivery and overall clinical development
Effective partnerships between advocacy and industry to expand collaborations that can support enrollment and physician engagement
Christopher Missling, President and CEO, Anavex Life Sciences
Steven Kaminsky, Chief Science Officer, International Rett Syndrome Foundation”
This is indicating that the Rett Foundation and Anavex have been working together pre-clinically to optimize drug discovery, that the Rett Foundation (and possibly other patient groups) have been guiding research, disease understanding and supporting pre-clinical development. I do not mean to say just the Anavex pre-clinical development, but certainly the Rett Foundation is supporting Anavex. It mentions effective partnerships in doing so. And, as you point out, Steven Kaminsky, Rett’s Chief Science Officer is appearing for this presentation that you mention. Although we have had much negative comment about why the Rett clinical trial has not commenced, the Rett Foundation and its Chief Science Officer most definitely is not viewing the situation as negative!
The negative opinions and speculation on this board are not evidence, but this is evidence that is favorable for this clinical trial.
